Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera

Leukemia Research Reports

Volumn 3, Issue 2, 2014, Pages 73-75

  Bjorn M E ^a   de Stricker, K ^b   Kjaer L ^a   Ellemann, K ^a   Hasselbalch, H C ^a  

^a ROSKILDE HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Combination therapy; Interferon; JAK2V617F allele burden; Polycythemia vera; Ruxolitinib

Indexed keywords

ANAGRELIDE; CLOPIDOGREL; HEMOGLOBIN; HYDROXYUREA; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PHENYLALANINE; RUXOLITINIB; VALINE;

ABDOMINAL DISCOMFORT; ABNORMAL SENSATION; ADULT; ALLELE; ARTICLE; BLOOD CELL COUNT; BONE MARROW BIOPSY; CASE REPORT; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; FEVER; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; LEUKOCYTE COUNT; LOW DRUG DOSE; MIDDLE AGED; MONOTHERAPY; MUSCLE WEAKNESS; PATIENT REFERRAL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RASH; REMISSION; SPLENOMEGALY; THROMBOCYTE COUNT; TRANSIENT ISCHEMIC ATTACK; ULTRASOUND;

EID: 84920858525     PISSN: 22130489     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lrr.2014.05.003     Document Type: Article

References (10)

1. Hasselbalch H.C. Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms. Expert Rev Hematol 2014, 7:203-216.
2. Hasselbalch H.C. The role of cytokines in the initiation and progression of myelofibrosis. Cytokine Growth Factor Rev 2013, 24:133-145.
3. Hasselbalch H.C. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?. Leuk Res 2013, 37:214-220.
4. Marty C., Lacout C., Droin N., Le Couédic J.-P., Ribrag V., Solary E., et al. A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression. Leukemia 2013, 27:2187-2195.
5. Verstovsek S., Mesa R.A., Gotlib J., Levy R.S., Gupta V., DiPersio J.F., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012, 366:799-807.
6. Essers M.A.G., Offner S., Blanco-Bose W.E., Waibler Z., Kalinke U., Duchosal M.A., et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 2009, 458:904-908.
7. Kiladjian J.-J., Cassinat B., Chevret S., Turlure P., Cambier N., Roussel M., et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008, 112:3065-3072.
8. Hasan S., Lacout C., Marty C., Cuingnet M., Solary E., Vainchenker W., et al. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα. Blood 2013, 122:1464-1477.
9. Silver R.T., Kiladjian J.-J., Hasselbalch H.C. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol 2013, 6:49-58.
10. Larsen T.S., Moller M.B., de S.K., Norgaard P., Samuelsson J., Marcher C., et al. Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission. Hematology 2009, 14:331-334.